Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0024141 (
systemic lupus erythematosus
)
44,322
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The metabolism of radioiodinated mouse IgG was studied in mice with
lupus
-like syndrome before and after the onset of the disease. Before the onset of the disease, the pharmacokinetic parameters of IgG in MLR-1pr and Pristane-primed Balb/c mice were within the normal range of values. After the onset of the disease a considerable increase in the catabolic rate of IgG was recorded abbreviating its half life to less than one third of the normal value. The increased catabolism of IgG could not be related to the concentration--catabolism effect or to the presence of rheumatoid factor and autoantibody or to the IgG loss through the kidney and gastrointestinal tract. The hypercatabolism of IgG was explained by disease-induced impairment of the function of the receptor
FcRn
, which regulates the homeostasis of IgG.
Lupus
2005
PMID:Hypercatabolism of IgG in mice with lupus-like syndrome. 1603 10
The role of DNA as the target for pathogenic
lupus
autoantibodies in
systemic lupus erythematosus
is equivocal and renal damage may be due to cross-reactivity of
lupus
Abs with glomerular components. We have previously shown that
lupus
autoantibodies bind to the laminin component of the extracellular matrix. In the present work, we have analyzed the fine specificity of the interaction of pathogenic murine
lupus
autoantibodies with this molecule and the effect of inhibiting their binding to laminin during the course of the disease. We have found that pathogenic murine
lupus
autoantibodies react with a 21-mer peptide located in the globular part of the
alpha-chain
of laminin. Immunization of young
lupus
-prone mice with this peptide accelerated renal disease. Analysis of transgenic, congenic, and RAG-1(-/-) mice confirmed the importance of this epitope in the pathogenesis of
lupus
renal disease. We have synthesized a panel of peptides that cross-react with the anti-laminin Abs and have found that the binding of
lupus
autoantibodies to the extracellular matrix could be inhibited in vitro by some of these competitive peptides. Treatment of MRL/lpr/lpr mice with these peptides prevented Ab deposition in the kidneys, ameliorated renal disease, and prolonged survival of the peptide-treated mice. We suggest that laminin components can serve as the target for
lupus
Abs. The interaction with these Ags can explain both the tissue distribution and the immunopathological findings in
lupus
. Moreover, inhibition of autoantibody binding to the extracellular matrix can lead to suppression of disease.
...
PMID:Treatment with a laminin-derived peptide suppresses lupus nephritis. 1621 Jun 60
The human IgA FcR (FcalphaRI; CD89) mediates a variety of immune system functions including degranulation, endocytosis, phagocytosis, cytokine synthesis, and cytokine release. We have identified a common, nonsynonymous, single nucleotide polymorphism (SNP) in the coding region of CD89 (844A-->G) (rs16986050), which changes codon 248 from AGC (Ser(248)) to GGC (Gly(248)) in the cytoplasmic domain of the receptor. The two different alleles demonstrate significantly different FcalphaRI-mediated intracellular calcium mobilization and degranulation in rat basophilic leukemia cells and cytokine production (IL-6 and TNF-alpha) in murine macrophage P388D1 cells. In the absence of FcR gamma-chain association in P388D1 cells, the Ser(248)-FcalphaRI allele does not mediate cytokine production, but the Gly(248)-FcalphaRI allele retains the capacity to mediate a robust production of proinflammatory cytokine. This allele-dependent difference is also seen with FcalphaRI-mediated IL-6 cytokine release by human neutrophils ex vivo. These findings and the enrichment of the proinflammatory Gly(248)-FcalphaRI allele in
systemic lupus erythematosus
populations in two ethnic groups compared with their respective non-
systemic lupus erythematosus
controls suggest that FcalphaRI (CD89)
alpha-chain
alleles may affect receptor-mediated signaling and play an important role in the modulation of immune responses in inflammatory diseases.
...
PMID:FcalphaRI (CD89) alleles determine the proinflammatory potential of serum IgA. 1733 98
A high-level expression of the Ea transgene encoding the MHC class II I-E
alpha-chain
is very effective in the protection from
systemic lupus erythematosus
(
SLE
) in mice. However, it has not been elucidated whether this protection results from the induction or increased expression of I-E heterodimers or from the generation of I-E
alpha-chain
-derived peptides displaying high affinity for I-A molecules, because previous studies were conducted in
lupus
-prone mice expressing I-E beta-chains. To address this question, we assessed the protective effect of the Ea transgene in
lupus
-prone BXSB mice bearing the H2(q) haplotype (i.e., unable to express I-E heterodimers because of a deficiency in I-E beta-chains). We observed that the Ea transgene expression resulted in a marked suppression of the development of
SLE
in H2(q) BXSB mice despite the absence of I-E expression. The observed protection was not associated with any detectable levels of T cell depletion and regulatory T cell expansion. Significantly, transgenic I-E alpha-chains were substantially expressed on the surface of B lymphocytes and dendritic cells, but not of macrophages, without apparent formation of mixed-isotype heterodimers with I-A beta-chains. Our results demonstrate for the first time that the Ea transgene is able to prevent the development of
SLE
without induction of I-E heterodimer expression, indicating a critical role of I-E alpha-chains, but not I-E heterodimers, in the Ea transgene-mediated protection from
SLE
. Taken together, our data favor a model of autoimmunity prevention based on competition for Ag presentation between I-E
alpha-chain
-derived peptides and autoantigens.
...
PMID:Protection of murine systemic lupus by the Ea transgene without expression of I-E heterodimers. 1871 40
<< Previous
1
2
3